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Background: Incisional hernia is the most frequently seen long term complication after laparotomy causing much
morbidity and even mortality. The overall incidence remains 11-20%, despite studies attempting to optimize closing
techniques. Two patient groups, patients with abdominal aortic aneurysm and obese patients, have a risk for
incisional hernia after laparotomy of more than 30%. These patients might benefit from mesh augmented midline
closure as a means to reduce incisional hernia incidence.
Methods/design: The PRImary Mesh Closure of Abdominal Midline Wound (PRIMA) trial is a double-blinded
international multicenter randomized controlled trial comparing running slowly absorbable suture closure with the
same closure augmented with a sublay or onlay mesh. Primary endpoint will be incisional hernia incidence 2 years
postoperatively. Secondary outcomes will be postoperative complications, pain, quality of life and cost effectiveness.
A total of 460 patients will be included in three arms of the study and randomized between running suture closure,
onlay mesh closure or sublay mesh closure. Follow-up will be at 1, 3, 12 and 24 months with ultrasound imaging
performed at 6 and 24 months to objectify the presence of incisional hernia. Patients, investigators and radiologists
will be blinded throughout the whole follow up.
Disccusion: The use of prosthetic mesh has proven effective and safe in incisional hernia surgery however its use
in a prophylactic manner has yet to be properly investigated. The PRIMA trial will provide level 1b evidence
whether mesh augmented midline abdominal closure reduces incisional hernia incidence in high risk groups.
Trial registration: Clinical trial.gov NCT00761475.Background
Incisional hernia (IH) is the most frequently seen long term
complication in surgery causing much morbidity and even
mortality in patients [1-4]. Despite studies on the optimal
closing technique for laparotomies, the risk for IH after
midline incision remains about 11-20% [5,6]. In the
Netherlands alone about 4000 IH operations are per-
formed each year. Incisional hernia surgery is, in fact, a
re-operation to relieve symptoms caused by this com-
mon complication and the results of repair are often
disappointing [7,8].* Correspondence: l.timmermans@erasmusmc.nl
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distribution, and reproduction in any mediumPatient-related risk factors for incisional hernia after a
laparotomy, like obesity, steroid use, malnutrition, smoking,
abdominal aortic aneurysm (AAA), and connective tissue
disorders are known [7,9-13]. Despite this knowledge a
sufficient method for prevention, has not been developed
yet. Most research in the field of incisional hernia surgery
has been performed to prevent recurrence after repair.
The closure technique of midline incisions has grosso
modo remained unchanged since many decades and pri-
marily consists of suturing the linea alba. Interest in pre-
vention of incisional hernias with the aid of synthetic
mesh is growing and small, yet promising studies have
now been published [14-25].Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Nieuwenhuizen et al. BMC Surgery 2013, 13:48 Page 2 of 9
http://www.biomedcentral.com/1471-2482/13/48One specific group of high-risk patients are patients
with an AAA. Aortic aneurysm is considered to be related
to a type of connective tissue disorder. The connective
tissue in these patients is thought to be compromised,
playing an important role in the pathogenesis of an
aneurysmal distension of the aorta. Healing of the midline
fascia after laparotomy may be compromised due to for-
mation of collagen with insufficient strength. Sutures can
tear through the fascia and defects can develop in the ab-
dominal wall. The relationship between aortic aneurysm
and other abdominal wall hernias, like inguinal hernias,
has been reported [26-28]. Retrospective and prospective
studies have shown an average risk for incisional hernia
after AAA repair of about 30% (Table 1) [9,26,28-34].
Another high risk group is the group of obese patients
[5]. Patients with a BMI of 30 or more have a high risk of
developing an incisional hernia after midline incision, with
an incidence of 22% after 12 months [5,13]. Most recent lit-
erature is showing us that even a BMI of more than 27
gives a 20% risk for developing an incisional hernia after
midline laparotomy [35]. Considering only 50% of incisional
hernia will be clinically evident in the first 12 months, the
total incidence is likely to be above 30%. It is known from
the study of Burger et al. that an extensive follow up time
of up to 10 years is needed to evaluate outcome in hernia
surgery [7]. A tailored approach might be necessary,
since hernia formation is multifactorial. Thus, the above
mentioned high-risk group of patients with obesity and
aneurysmal disease can benefit most from prevention.
Some small studies have been performed to evaluate
the effect and safety of primary laparotomy wound clos-
ure with the aid of prosthetic mesh (Table 2) [14-25].
These studies show a very low risk for incisional hernia
and a low infection rate, even when used in contami-
nated area’s, as seen in colostomy surgery. However, no
high quality and adequately powered randomized con-
trolled trial has been performed to evaluate the impact
of prophylactic mesh augmentation for prevention ofTable 1 Publications concerning risk for incisional hernia afte
minimum of 2 years follow-up
Author Year Follow-up A
Fassiadis et al. [9] 2005 50 months R
Rodriguez et al. [29] 2004 36 months P
Liapis et al. [30] 2004 63 months P
Raffetto et al. [28] 2003 33 months P
Augestad et al. [31] 2002 42 months C
Musella et al. [32] 2001 49 months P
Adye and Luna [26] 1998 36 months R
Holland et al. [33] 1996 24 months C
Stevick et al. [34] 1988 38 months Rincisional hernia in high risk patients. This is the reason
that the PRImary Mesh Closure of Abdominal Midline
Wound (PRIMA) trial is being conducted.
Objective
The objective of this study is to evaluate the effectiveness
of incisional hernia prevention in patients after laparot-
omy for aortic aneurysm and in obese patients with a BMI
of more than 27. A double blind randomized controlled
trial will compare the commonly used technique of run-
ning suture to closure with the aid of a prosthetic mesh.
 The primary outcome measure will be incisional
hernia occurrence 2 years postoperatively.
 Secondary outcome measures will cover relevant
postoperative complications, post-operative pain and
quality of life.
Methods/design
Trial design
The trial is a double blinded randomized controlled inter-
national multi centre trial comparing traditional closure
with running slowly absorbable suture to closure with the
aid of prosthetic mesh. A total of 11 centers have agreed to
participate in the trial which are located in three different
countries (The Netherlands, Germany and Austria). A total
number of 460 patients will be included. Patients will be
randomized in three groups per-operatively to either re-
ceive primary closure, or mesh supported closure either in
a sublay or onlay position. Patients will be kept unaware of
the procedure until the endpoint of the trial was assessed.
Outpatient clinic controls will be done by surgeons or sur-
gical residents blinded for the procedure. Results will be
stratificated by center and operation indication.
Participants
Patients meeting the inclusion criteria scheduled for
elective laparotomy will be asked to participate in ther aortic aneurysm repair with midline incision with a
rticle type # Hernias # AAA %
CT 20 22 90,9
rospective 14 61 22,9
rospective 32 197 16,2
rospective 50 177 28,2
ase series 49 140 35
rospective 16 51 31,4
etrospective 18 58 31,0
ase series 13 34 38,2
etrospective 10 27 37,0
Table 2 Publications concerning incisional hernia prevention with the aid of prosthetic mesh
Author Year Type article # Patients Hernia primary Hernia Mesh Follow-up Mesh type Mesh position
G. Currò et al. [14] 2011 Prospective 95 15/50 2/45 24 months Polypropylene Sublay
O. H. Llaguna et al. [15] 2011 Prospective 134 11/62 1/44 17 months Biological Intraperitoneal
P. M. Bevis et al. [16] 2010 RCT 85 16/43 5/37 36 months Polypropylene Sublay
G. Currò et al. 2010 Prospective 50 8/25 1/25 12 months Polypropylene Sublay
M. P. Hidalgo et al. 2010 Cohort 72 - 0/72 46 months Polypropylene Onlay
O. H. El-Khadrawy et al. [19] 2009 RCT 40 1/20 3/20 36 months Polypropylene Preperitonial
G. Hebert et al. 2009 Cohort 16 - 1/16 6 months Mix Sublay
J. Strzelczyk et al. [21] 2006 RCT 74 8/38 0/36 28 months Polypropylene Sublay
J.L. O’Hare et al. [22] 2007 Cohort 39 - 1/28 48 months Polypropylene Sublay
C. Gutierrez de la Pena et al. [23] 2003 RCT 88 5/44 0/44 36 months Polypropylene Onlay
J. Strzelczyk et al. [24] 2002 Prospective 60 9/48 0/12 12 months Polypropylene Sublay
A. Pans [25] 1998 RCT 288 41/144 33/144 29 months Vicryl Intraperitoneal
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will be asked for informed consent.
Inclusion criteria
 Every elective midline laparotomy for patients with
Abdominal Aortic Aneurysm AND/OR patients
with a BMI of more than 27a.
 Signed informed consent
Exclusion criteria
 Age < 18 years
 Inclusion in other trials with interference of the
primary endpoint
 Life expectancy less than 24 months (as estimated
by the treating physician)
 Pregnant women
 Immune suppression therapy within 2 weeks before
surgery
 Bovine allergy
Registration and randomization procedure
Patients who are scheduled for operation and who have
given informed consent will be registered by contacting
the trial coordinator using the telephone or using the on-
line inclusion randomization system. Included patient are
registrated in an online data base (designed and managed
by HOVON data center, Rotterdam, the Netherlands)
called TOP (Trial Online Process; see http://www.prima-
trial.nl). The patient name code, date of birth, name of
caller, name of responsible physician, sex and eligible cri-
teria will be registered. Every participating institution has
its own login code.
Randomisation will take place at the end of the sched-
uled operation before closing the abdomen in the oper-
ating room by contacting the trial coordinator using thetelephone or using the online inclusion randomization
system. The patient will stay in the randomization group
on an intention to treat principle.
Intervention
Patients will be randomized for three different closing
techniques (1A: primary suture closure of the midline
fascia, 2B onlay mesh supported closure and 3C sublay
mesh supported closure). Both mesh techniques are exten-
sively used in incisional hernia surgery. However, a pow-
ered randomized comparison of these two techniques has
not been performed. Infection rates in these trials seem
low, even in the presence of open bowel [36-41]. Because
the study population will not be operated for an incisional
hernia, which necessitates extended dissection of the ab-
dominal wall in a previously operated area, infection rates
are expected to be lower than the rates mentioned in the
literature. Intra-peritoneal placement has not been consid-
ered given the high risk for adhesions between viscera and
mesh [42].
The mesh will be fixed to the fascia structures with fibrin
sealant (Tissucol DUO 500 2,0 ml (Baxter Deutschland
GmbH, Unterschließheim, Germany) in order to avoid su-
tures subcutaneously, to prevent the production of seroma
and to simplify the procedure [43]. Nowadays fibrin seal-
ants are occasionally used in inguinal hernia surgery
[44-46]. The mesh will be fixed adequately with fibrin
sealant to the ventral part of linea alba and posterior
rectus sheath. The Optilene Mesh LP, 6 × 35 cm, B.
Braun Aesculap AG, Tuttlingen, Germany, will be used
as it was shown to have an optimal fixation with fibrin
sealant and to provide good tensile strength [47].
Only the first operations of each center will be super-
vised by one of the PRIMA trial research fellows. If dur-
ing operation an incisional hernia was discovered the
patient was excluded from the trial, as the interest of
this study was incisional hernia prevention, not repair.
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wound length ratio concept although not measured. As
the focus of the trial was on the effect of primary mesh
augmentation versus common day practice closure, no
measurements of the suture closure were done.
Group A. Primary closure of the midline
The midline fascia will be closed in all three groups with a
running slowly absorbable suture (MonoPlus, USP 1, Needle
HRT48, 150 cm loop, B.Braun Aesculap, Tuttlingen,
Germany). The ratio of suture length to wound length of 4:1
is recommended (but not measured). Subcutaneous tissue
and skin are closed in a fashion preferred by the surgeon.
Mesh supported closure
Group B. Onlay mesh supported closure
First, the midline will be closed as indicated in group A.
The Optilene Mesh LP will be positioned on the pri-
mary closed midline fascia with an overlap of 3 cm at
each side. The mesh will then be fixed with fibrin sealant
(5 ml). The fibrin sealent will be applied on the entire
surface of the mesh, and in one shot having permanent
contact between the mesh and the tip of the joining
piece. Immediately after application of the fibrin sealant,
the mesh will be smoothed with the back of a forceps to
get a good fixation of the mesh on the entire surface and
especially on the suture line. If present, it is also possible
to use spray fixation using the EASYSPRAY system,
Deutschland GmbH, Unterschließheim, Germany. When
laparotomy is larger then 25 cm use 2 applicators of Tis-
sucol (10 ml). Subcutaneous tissue and skin are closed
in a fashion preferred by the surgeon.
Group C. Sublay mesh supported closure
A space will be created between both posterior rectus
sheaths and the rectus muscle. Both posterior rectus sheath
edges are sutured using a running slowly absorbable suture,
(Monoplus, USP1, Needle HRT48, 150 cm, B. Braun
Aesculap AG, Tuttlingen, Germany). A suture length to
wound length ratio of 4:1 was recommended (not mea-
sured). The Optilene Mesh LP will then be placed be-
tween the posterior rectus sheath and the rectus
muscle with an overlap of 3 cm at each side and fixed
with fibrin sealant (5 ml). The fibrin sealent will be ap-
plied on the entire surface of the mesh, in one shot
having permanent contact between the mesh and the tip
of the joining piece. Immediately after application of the fi-
brin sealant, the mesh will be smoothed with the back of a
forceps to get a good fixation of the mesh on the entire sur-
face and especially on the suture line. If present, it is also
possible to use spray fixation using the EASYSPRAY system,
Deutschland GmbH, Unterschließheim, Germany. When
laparotomy is >25 cm use 2 applicators of Tissucol (10 ml).
The midline anterior rectus sheath will be closed using arunning slowly absorbable suture (Monoplus, USP1, Needle
HRT48, 150 cm, B. Braun Aesculap AG, Tuttlingen,
Germany), covering the mesh. A suture length to wound
length ratio of 4:1 was recommended (not measured). Sub-
cutaneous tissue and skin will be closed in a fashion pre-
ferred by the surgeon.
Postoperative treatment:
Wound drainage will not be routinely applied. Seromas
do not have to be punctured or drained, but can be left
untreated to resolve spontaneously.
Implementation
Pre-operative data
 Date of birth
 Length and weight
 Smoking history (current smoker ( Y or N )
 Medical history (COPD, diabetes, cardiac disease)
 Preoperative Radiotherapy or chemotherapy
 Preoperative corticosteroids
 Postoperative corticosteroids
 Previous abdominal operations
 Other abdominal hernias (inguinal, umbilical,
epigastric hernias)
 ASA class
 Width of linea alba (when pre-operative C.T.
imaging is available)
 Size of aneurysm and location
 Epidural catheter
Operation data
 Type of operation
 Type and length of prosthesis
 Volume of fibrin sealant applied
 Length of incision
 Blood loss
 Operation time
 Antibiotic prophylaxis
 Suture material
 Drains and location
 Thrombosis prophylaxis
 Pain medication
 Complications (intestinal lesions, bleeding, other)
Post-operative data
 Blood transfusion
 Postoperative ventilation and duration
 Postoperative ileus and duration
 Postoperative complications:○ Surgical Site Infection, according to the guidelines
proposed by Mangram in 1999 [48]. (Appendix)
Tabl
Evalu
P
(1) MO
(2) EQ
(3) VA
Nieuwenhuizen et al. BMC Surgery 2013, 13:48 Page 5 of 9
http://www.biomedcentral.com/1471-2482/13/48○ Wound hematoma: accumulation of blood in
the wound area, which warrants surgical
exploration and intervention.
○ Seroma subcutaneously
○ Pulmonary infections
○ Ventilation problems
○ Re-intervention and difficulties caused by the
mesh at re-entry
○ Re-admission and indicationUltrasound examination
At 6 and 24 months ultrasound imaging will be per-
formed to examine the midline for any asymptomatic
clinically not detectable incisional hernias. This will pro-
vide valuable information about the onset of an inci-
sional hernia. Size and location of all incisional hernias
noted radiographically will be registered, as well as com-
plaints presented by the patients. Endpoint of this study
will be at 2 years follow up. At this follow-up the pres-
ence of a hernia will be investigated by physical examin-
ation and ultrasound imaging.
Outpatient follow-up
The follow-up schedule is displayed in Table 3. During
visits the following information will be gathered.
 Outpatient clinic visit at 1, 3, 12 and 24 months
○ Incisional hernia
○ Wound infection
○ Seroma formation
○ Other wound problems
○ Inguinal hernia
 Ultrasound at 6 and 24 months
 VAS score at 1 month
 VAS scores and Quality of Life forms preoperatively
( day of operation or the day before) and at 3, 12
and 24 months
Economical evaluation
Cost effectiveness will be calculated after 2 years. The
direct costs, admissions, operation costs, costs of mate-
rials and treatment of complications and incisionale 3 Follow up schedule
ation moments MOS SF-36 (1) EQ-5D (2)
re-operative X X
1 month
3 months X X
12 months X X
24 months X X
S SF-36: Questionnaire concerning quality of life (SF-36 ™ Health Survey, Med
-5D: Euro Qol Group quality of life questionnaire.
S score: Pain measurement tool on which patients can define their pain on ahernias, will be calculated. Quality Adjusted Life Years
will be calculated.
An incisional hernia correction costs Є3777,-. When
100 patients are operated with the aid of a mesh in-
sertion we estimate to prevent 15 incisional hernias
(=Є56.655,-). One hundred meshes cost approximately
Є30.000,-. We would save Є26.655,- if all incisional her-
nias are repaired. We did not include all extra costs as
for example visits to the general practitioner, but these
will be included in our final analysis.Statistical analysis
Three comparisons will be made leading to pair-wise com-
parison at alpha = 0.017 (=0.05/3) according to Bonferroni’s
correction for multiple testing. Assuming a 30% rate of in-
cisional hernia in group A, and about 10% in both groups
B and C, for a power of 90% comparing group A versus
group B and C, 92 patients are required in group A and
164 in groups B and C. Allowing for some dropouts, 100
will be included in the control group and 180 in each ex-
perimental group.
It is expected that differences between groups B and C
can only be demonstrated with a very large number.
Therefore it was decided to set the objective to showing
“non inferiority” for onlay (group C) versus sublay (group
B). Setting the non-inferiority margin at 10%, the power to
show non-inferiority regarding the incidence rate of inci-
sional hernia will be greater than 80%.
For the comparison of both experimental groups with
the control group, Kaplan-Meier curves will be con-
structed and the log-rank tests will be performed. These
logrank tests will be done with stratification by center
and operation indication.
For the comparison of both experimental groups B
and C, the cumulative 2-years probability will be calcu-
lated with the one-sided 98.3% confidence interval for
the difference. Analysis will be done according to the
intention-to-treat principle in comparing group A with
groups B and C. For the comparison of groups B and C
a per-protocol analysis will be the primary analysis.
Comparison of VAS and QOL scales between groups
will be done using Repeated Measures Anova (SAS PROCVAS score (3) Outpatient clinic Ultrasound
X
X X
X X X at 6 months
X X
X X X
ical outcomes Trust, Boston, Massachusetts 02116, USA).
sliding scale.
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tion and center as covariates.
The following putative risk factors regarding incisional
hernia (smoking, infection, diabetes, corticosteroids) will
be evaluated using Cox-regression.
Serious Adverse Event (SAE) reporting & Monitoring
A SAE will be reported to the Dutch Department for
Human Research (Centrale Commissie Mensgebonden
Onderzoek), Baxter and Braun within 24 hours.
Requirements for SAE reporting will be:
1. (Prolonged) Hospitalisation (difined as a longer stay
in the hospital than normally expected caused by a
postoperative complication)
2. (Re-)operation
3. Death
Once a year, data from each center will be monitored.
In compliance with GCP guidelines, monitors will verify
data collected on data collection forms against source
documents. Source documents are defined as any ori-
ginal records or data related to the trial or to subject
treatment or medical history. Source documents include:
original hospital, clinical, and office charts, laboratory
notes, subject diaries or evaluation checklists, pharmacy
records, recorded data from automated instruments,
transcriptions (certified to be accurate after verification),
magnetic media, or x-rays.
Ethics
Before centers could participate in this trial, approval
was obtained from the local medical ethics committee
(Medische Ethische Toetsings Commissie, Erasmus MC).
Patients will be extensively informed about the research
project and can only participate after giving informed con-
sent. Patients will always be permitted to withdraw from
the study without providing further reasons. This will have
no consequences for further treatment. Data of these pa-
tients will be evaluated in the final analysis. This trial was
registered at Clinical trial.gov under NCT00761475.
History and current status
After Ethical approval was obtained the trial started in-
cluding patients in the middle of 2009. Initially the in-
take of patients was rather slow. This was attributed to
the the low number of participating hospitals, the con-
tinued increase of laparoscopy and endovascular treat-
ment, and the inclusion criteria of BMI >30. After the
publication of Seiler et al. the BMI inclusion criteria
were lowered from 30 to 27 [35]. The BMI amendment
and the inclusion of additional participating hospitals
made it possible to include more patients per month.
Currently the trial is in the final stage of the inclusion ofpatients. It is estimated that the last patients will be seen
in the outpatient clinic in the beginning of 2015. Around
this time the final results will be subjected to peer-
review for publication.
Discussion
Incisional hernia continues to be one of the most frequent
complications after laparotomy. Up to this date no inter-
vention strategy has led to a resolution to this problem. In
high risk patients, with a risk for incisional hernia more
than 30%, an alternative technique with lower incisional
hernia incidence would be highly desirable.
In daily practice almost all midline laparotomies are
closed with slowly absorbable running sutures. This
technique seems ample for low risk patients. Despite the
high incidence of incisional hernia, this technique is still
used in high risk patients. These patients are known to
have altered collagen synthesis in wound repair or in-
creased abdominal wall stress, leading to insufficient re-
pair of the midline after operation.
In incisional hernia surgery the use of prosthetic mesh
has proven its effectiveness and safety. For this reason a
RCT investigating the effectiveness and safety of aug-
menting the closure of the midline with prosthetic mesh
in high risk patients is being conducted. A high level of
evidence will be obtained due to the design of the study,
as it was a randomized, double blind, powered, multi-
center study.
Conclusion
The PRIMA trial is a prospective international multicen-
ter double blind randomized trial comparing primary su-
ture closure of midline laparotomy to closure aided with
a prosthetic mesh. This trial might provide the surgical
society a technique to prevent incisional hernia in high
risk patients.
Endnote
aThe initial inclusion criteria featured patients with a
BMI of 30 or higher. However as stated before, a study
was published during the enrolment of this trial demon-
strating that patients with a BMI 27 or more could also
be included [35]. We amended our protocol to lower
our inclusions criteria for BMI, from 30 to 27.
Appendix
Criteria for defining a Surgical Site Infection (SSI) [49]
Superficial Incisional SSI
Infection occurs within 30 days after the operation and
infection involves only skin or subcutaneous tissue of
the incision and at least one of the following:
1. Purulent drainage, with or without laboratory
confirmation, from the superficial incision.
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culture of fluid or tissue from the superficial incision.
3. At least one of the following signs or symptoms of
infection: pain or tenderness, localized swelling,
redness or heat and superficial incision is deliberately
opened by surgeon, unless incision is culture-negative.
4. Diagnosis of superficial incisional SSI by the
surgeon or attending physician.
5. Do not report the following conditions as SSI:
6. Stitch abscess (minimal inflammation and discharge
confined to the points of suture penetration).
7. Incisional SSI that extends into the fascial and
muscle layers (see deep incisional SSI).
Deep incisional SSI
Infection occurs within 30 days after the operation if no
implant is left in place or within 1 year if implant is in
place and the infection appears to be related to the oper-
ation and infection involves deep soft tissue (e.g., fascial
and muscle tissue) of the incision and at least one of the
following:
1. Purulent drainage from the deep incision but not
from the organ/space component of the surgical site.
2. A deep incision spontaneously dehisces or is
deliberately opened by a surgeon when the patient
has at least one of the following signs or symptoms:
fever (>38°C), localized pain, or tenderness, unless
site is culture negative.
3. An abscess or other evidence of infection involving
the deep incision is found on direct examination,
during re-operation, or by histopathologic or
radiological examination.
4. Diagnosis of a deep incisional SSI by a surgeon or
attending physician.
Notes:
1. Report infection that involves both superficial and
deep incision sites as deep incisional SSI.
2. Report an organ/space SSI that drains through the
incision as a deep incisional SSI.
Organ/Space SSI
Infection occurs within 30 days after the operation if no
implant is left in place or within 1 year if implant is in
place and the infection appears to be related to the oper-
ation and infection involves any part of the anatomy (e.
g., organs or spaces), other than the incision, which was
opened or manipulated during an operation and at least
one of the following:
1. Purulent drainage from drain that is placed through
a stab wound into the organ/space.2. Organisms isolated from an aseptically obtained
culture of fluid or tissue in the organ space.
3. An abscess or other evidence of infection involving
the organ/space that is found on direct examination,
during reoperation, or by histopathologic or radiologic
examination.
4. Diagnosis of a deep organ/space SSI by a surgeon
or attending physician.
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